Machina Capital S.A.S. Reduces Position in Chemed Corporation $CHE

Machina Capital S.A.S. decreased its holdings in shares of Chemed Corporation (NYSE:CHE) by 22.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 478 shares of the company’s stock after selling 141 shares during the quarter. Machina Capital S.A.S.’s holdings in Chemed were worth $233,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Renasant Bank grew its holdings in shares of Chemed by 2.3% during the first quarter. Renasant Bank now owns 815 shares of the company’s stock worth $501,000 after buying an additional 18 shares in the last quarter. Cim LLC grew its holdings in shares of Chemed by 1.0% during the first quarter. Cim LLC now owns 2,029 shares of the company’s stock worth $1,248,000 after buying an additional 21 shares in the last quarter. Cynosure Group LLC grew its holdings in shares of Chemed by 4.3% during the first quarter. Cynosure Group LLC now owns 581 shares of the company’s stock worth $358,000 after buying an additional 24 shares in the last quarter. Atria Investments Inc grew its holdings in shares of Chemed by 0.6% during the second quarter. Atria Investments Inc now owns 4,259 shares of the company’s stock worth $2,074,000 after buying an additional 25 shares in the last quarter. Finally, Brogan Financial Inc. grew its holdings in shares of Chemed by 7.3% during the first quarter. Brogan Financial Inc. now owns 426 shares of the company’s stock worth $262,000 after buying an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Oppenheimer dropped their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and upped their price objective for the company from $490.00 to $550.00 in a report on Tuesday, September 2nd. Finally, Bank of America dropped their price objective on shares of Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $578.50.

Insider Activity

In other Chemed news, CEO Kevin J. Mcnamara sold 3,000 shares of the stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the transaction, the chief executive officer owned 96,197 shares of the company’s stock, valued at $44,373,752.16. This trade represents a 3.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Patrick P. Grace sold 150 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the sale, the director directly owned 3,397 shares in the company, valued at $1,574,135.83. This represents a 4.23% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.29% of the company’s stock.

Chemed Price Performance

Shares of CHE stock opened at $438.94 on Wednesday. The firm has a market cap of $6.40 billion, a PE ratio of 23.21, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43. The company has a 50-day moving average of $447.22 and a two-hundred day moving average of $490.18. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60.

Chemed (NYSE:CHE) last announced its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing the consensus estimate of $5.39 by ($0.12). The company had revenue of $624.90 million for the quarter, compared to analysts’ expectations of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the business earned $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Sell-side analysts anticipate that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.